Search Results

There are 9338 results for: content related to: The effects of bortezomib on bone disease in patients with multiple myeloma

  1. You have free access to this content
    Bortezomib-containing induction regimens in transplant-eligible myeloma patients

    Cancer

    Volume 119, Issue 23, 1 December 2013, Pages: 4119–4128, Ajay K. Nooka, Jonathan L. Kaufman, Madhusmita Behera, Amelia Langston, Edmund K. Waller, Christopher R. Flowers, Charise Gleason, Lawrence H. Boise and Sagar Lonial

    Version of Record online : 4 SEP 2013, DOI: 10.1002/cncr.28325

  2. You have free access to this content
    A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

    Cancer

    Volume 121, Issue 19, October 1, 2015, Pages: 3465–3471, Timothy S. Fenske, Namrata M. Shah, Kyung Mann Kim, Sandeep Saha, Chong Zhang, Arielle E. Baim, John P. Farnen, Adedayo A. Onitilo, Jules H. Blank, Harish Ahuja, Tim Wassenaar, Rubina Qamar, Patrick Mansky, Anne M. Traynor, Ryan J. Mattison and Brad S. Kahl

    Version of Record online : 16 JUN 2015, DOI: 10.1002/cncr.29502

  3. You have free access to this content
    Bortezomib for the treatment of multiple myeloma

    Intervention Review

    The Cochrane Library

    Kathleen Scott, Patrick J Hayden, Andrea Will, Keith Wheatley and Imelda Coyne

    Published Online : 20 APR 2016, DOI: 10.1002/14651858.CD010816.pub2

  4. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

    Cancer

    Volume 122, Issue 13, July 1, 2016, Pages: 2050–2056, Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hajek, Andrew Spencer, Tadeusz Robak, Anna Dmoszynska, Noemi Horvath, Ivan Spicka, Heather J. Sutherland, Alexander N. Suvorov, Liang Xiu, Andrew Cakana, Trilok Parekh and Jesús F. San-Miguel

    Version of Record online : 18 MAY 2016, DOI: 10.1002/cncr.30026

  5. You have free access to this content
    Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma

    Cancer

    Volume 121, Issue 13, July 1, 2015, Pages: 2185–2192, Ruth Seggewiss-Bernhardt, Ralf C. Bargou, Yeow Tee Goh, A. Keith Stewart, Andrew Spencer, Adrian Alegre, Joan Bladé, Oliver G. Ottmann, Cristina Fernandez-Ibarra, Hong Lu, Scott Pain, Mikhail Akimov and Swaminathan Padmanabhan Iyer

    Version of Record online : 24 MAR 2015, DOI: 10.1002/cncr.29339

  6. You have free access to this content
    Autologous retransplantation for patients with recurrent multiple myeloma

    Cancer

    Volume 119, Issue 13, 01 July 2013, Pages: 2438–2446, Leopold Sellner, Christiane Heiss, Axel Benner, Marc S. Raab, Jens Hillengass, Dirk Hose, Nicola Lehners, Gerlinde Egerer, Anthony D. Ho, Hartmut Goldschmidt and Kai Neben

    Version of Record online : 10 APR 2013, DOI: 10.1002/cncr.28104

  7. You have free access to this content
    Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically

    BJU International

    Volume 109, Issue 8, April 2012, Pages: 1258–1268, Akinori Sato, Takako Asano, Keiichi Ito, Makoto Sumitomo and Tomohiko Asano

    Version of Record online : 2 SEP 2011, DOI: 10.1111/j.1464-410X.2011.10533.x

  8. You have free access to this content
    A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma

    Cancer

    Volume 122, Issue 21, November 1, 2016, Pages: 3327–3335, Ajai Chari, Myo Htut, Jeffrey A. Zonder, Joseph W. Fay, Andrzej J. Jakubowiak, Joan B. Levy, Kenneth Lau, Steven M. Burt, Brian J. Tunquist, Brandi W. Hilder, Selena A. Rush, Duncan H. Walker, Mieke Ptaszynski and Jonathan L. Kaufman

    Version of Record online : 19 JUL 2016, DOI: 10.1002/cncr.30174

  9. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

    Molecular Carcinogenesis

    Volume 52, Issue 2, February 2013, Pages: 118–133, Daniel R. Premkumar, Esther P. Jane, Naomi R. Agostino, Joseph D. DiDomenico and Ian F. Pollack

    Version of Record online : 15 NOV 2011, DOI: 10.1002/mc.21835

  10. You have free access to this content
    Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies

    Cancer

    Volume 119, Issue 24, 15 December 2013, Pages: 4308–4315, Brian L. Burnette, Angela Dispenzieri, Shaji Kumar, Ann M. Harris, Jeff A. Sloan, Jon C. Tilburt, Robert A. Kyle and S. Vincent Rajkumar

    Version of Record online : 19 SEP 2013, DOI: 10.1002/cncr.28340

  11. You have free access to this content
    Proteasome inhibition aggravates tumor necrosis factor–mediated bone resorption in a mouse model of inflammatory arthritis

    Arthritis & Rheumatism

    Volume 63, Issue 3, March 2011, Pages: 670–680, Karin Polzer, Kirsten Neubert, Silke Meister, Benjamin Frey, Wolfgang Baum, Jörg H. Distler, Eva Gückel, Georg Schett, Reinhard E. Voll and Jochen Zwerina

    Version of Record online : 25 FEB 2011, DOI: 10.1002/art.30177

  12. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines

    International Journal of Laboratory Hematology

    Volume 34, Issue 3, June 2012, Pages: 237–247, B. ZHENG, R. ZHOU, Y. GONG, X. YANG and Q. SHAN

    Version of Record online : 7 DEC 2011, DOI: 10.1111/j.1751-553X.2011.01384.x

  13. You have full text access to this Open Access content
    Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition

    Cancer Science

    Volume 101, Issue 6, June 2010, Pages: 1403–1408, Daisuke Tamura, Tokuzo Arao, Kaoru Tanaka, Hiroyasu Kaneda, Kazuko Matsumoto, Kanae Kudo, Keiichi Aomatsu, Yoshihiko Fujita, Takashi Watanabe, Nagahiro Saijo, Yoshikazu Kotani, Yoshihiro Nishimura and Kazuto Nishio

    Version of Record online : 15 MAR 2010, DOI: 10.1111/j.1349-7006.2010.01544.x

  14. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer

    Journal of Surgical Oncology

    Volume 105, Issue 4, 15 March 2012, Pages: 357–364, Annette Wunderlich, Tjadina Arndt, Melina Fischer, Silvia Roth, Annette Ramaswamy, Brandon H. Greene, Cornelia Brendel, Ulrike Hinterseher, Detlef K. Bartsch and Sebastian Hoffmann

    Version of Record online : 17 OCT 2011, DOI: 10.1002/jso.22113

  15. You have free access to this content
    Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: 314–319, María Victoria Mateos, Paul G. Richardson, Meletios A. Dimopoulos, Antonio Palumbo, Kenneth C. Anderson, Hongliang Shi, Jennifer Elliott, Edward Dow, Helgi van de Velde, Liviu Niculescu and Jesús F. San Miguel

    Version of Record online : 27 FEB 2015, DOI: 10.1002/ajh.23933

  16. Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells

    Journal of Periodontal Research

    Volume 50, Issue 2, April 2015, Pages: 248–255, J. Kitagaki, S. Miyauchi, C. J Xie, M. Yamashita, S. Yamada, M. Kitamura and S. Murakami

    Version of Record online : 20 JUN 2014, DOI: 10.1111/jre.12202

  17. You have free access to this content
    Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

    American Journal of Hematology

    Volume 84, Issue 10, October 2009, Pages: 657–660, Raman Sood, Harry Carloss, Robert Kerr, Jose Lopez, Martin Lee, Mark Druck, Ian B. Walters and Stephen J. Noga

    Version of Record online : 30 JUL 2009, DOI: 10.1002/ajh.21517

  18. You have full text access to this Open Access content
    Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1

    Cancer Science

    Volume 100, Issue 2, February 2009, Pages: 341–348, Masaki Ri, Shinsuke Iida, Takashi Ishida, Asahi Ito, Hiroki Yano, Atsushi Inagaki, Jianmin Ding, Shigeru Kusumoto, Hirokazu Komatsu, Atae Utsunomiya and Ryuzo Ueda

    Version of Record online : 5 DEC 2008, DOI: 10.1111/j.1349-7006.2008.01038.x

  19. You have free access to this content
    A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

    British Journal of Haematology

    Volume 127, Issue 2, October-II 2004, Pages: 165–172, S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin, P. G. Richardson, R. Niesvizky, R. Alexanian, S. A. Limentani, M. Alsina, J. Adams, M. Kauffman, D.-L. Esseltine, D. P. Schenkein and K. C. Anderson

    Version of Record online : 27 SEP 2004, DOI: 10.1111/j.1365-2141.2004.05188.x

  20. You have free access to this content
    Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction

    British Journal of Haematology

    Volume 146, Issue 3, August 2009, Pages: 270–281, Tae Young Kim, Jongmin Park, Bora Oh, Hyun Jung Min, Tae-Sook Jeong, Jae Hoon Lee, Cheolwon Suh, June-Won Cheong, Hyo Jung Kim, Sung-Soo Yoon, Seung Bum Park, Dong Soon Lee and the Korean Multiple Myeloma Working Party (KMMWP)

    Version of Record online : 3 JUN 2009, DOI: 10.1111/j.1365-2141.2009.07752.x